GlassScriptPhysician profile
Tammy D Hadley
NPI 1598766958
$886.68
in general payments reported to CMS, 2019-2025
12 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $84.82 · 2024: $439 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $163.40 | 2024-2025 | |
| Novo Nordisk INC | $156.10 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $119.48 | 2023-2025 | |
| Amgen INC. | $101.22 | 2023-2024 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $80.31 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.96 | 2023-2025 | Tradjenta, Synjardy, Jardiance |
| Sumitomo Pharma America, INC. | $46.24 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $39.10 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $35.28 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2023-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $25.46 | 2024 | |
| Esperion Therapeutics, INC. | $14.23 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Hadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.